Hypoallergenicity of a Hydrolyzed Rice Protein-Based Formula Containing 2-Fucosyllactose and Lacto-N-Neotetraose in Children with Cow’s Milk Allergy: Protocol for a Randomized Controlled Study. The RIGHT-HY Study

Why It Matters

Demonstrating hypoallergenicity will give clinicians a plant‑based, HMO‑enriched alternative to amino‑acid formulas, expanding safe nutrition options for CMA infants and potentially improving gut health outcomes.

Key Takeaways

• RIGHT‑HY enrolls up to 67 CMA infants for hypoallergenicity testing
• HRF‑HMO contains 1.5 g/L of 2’FL and LNnT, matching AAF‑HMO
• Primary endpoint: ≥90 % of children pass double‑blind challenge with HRF‑HMO
• Secondary outcomes track gastrointestinal tolerance and adverse events during a 7‑day home phase

Pulse Analysis

The emergence of hydrolyzed rice formulas (HRF) has offered a plant‑based alternative to traditional cow‑milk‑derived extensively hydrolyzed formulas for infants with cow’s milk allergy (CMA). While HRF are already endorsed by ESPGHAN and the World Allergy Organization, their clinical profile has lacked the added functional benefits of human milk oligosaccharides (HMOs). By incorporating 2‑fucosyllactose (2’FL) and lacto‑N‑neotetraose (LNnT) at 1.5 g/L, the RIGHT‑HY study aims to combine the low allergenicity of rice protein with the microbiome‑modulating effects of HMOs, potentially narrowing the gap between formula feeding and breast‑milk nutrition.

From a market perspective, the infant formula sector is rapidly expanding its HMO portfolio, yet most HMO‑fortified products remain cow‑milk‑based, limiting options for CMA patients. If the trial meets the American Academy of Pediatrics hypoallergenicity criterion—90 % tolerance under double‑blind, placebo‑controlled food challenge—HRF‑HMO could become the first evidence‑backed, plant‑based, HMO‑enriched formula. This would give pediatricians a nutritionally complete, lactose‑free alternative that also supports gut health, possibly reducing infection rates and antibiotic use, outcomes already linked to HMO supplementation in other studies.

Beyond immediate clinical implications, the RIGHT‑HY protocol sets a methodological benchmark for future formula trials. Its crossover design, interim analysis plan, and comprehensive safety monitoring provide a robust framework for evaluating novel ingredient combinations. Successful results could spur further research into synergistic effects of plant proteins and bioactive oligosaccharides, encouraging manufacturers to diversify formula offerings while adhering to stringent hypoallergenicity standards. Such advances would ultimately broaden safe feeding strategies for the growing population of infants with CMA worldwide.